SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AKBA

Akebia Therapeutics, Inc. (NASDAQ:AKBA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.39-$0.04 (-8.71%)
 
Market cap
$107M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 20, 2014
Website
Market Cap$107.04M-75.8%
Revenue (ttm)$197.19M-12.4%
Net Income-$44.56M-180.2%
EPS-$0.16-122.8%
Shares Out277.66M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,565,298
Open$0.41
Previous Close$0.42
Day's Range$0.38 - $0.43
52-Week Range$0.36 - $1.73
Beta0.23
AnalystsBuy
Price Target$1.00(+159.40%)
Earnings DateFeb 25, 2027

About AKBA

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Address
180 Third Avenue, Waltham, MA, 02451, US
Market Cap
107 million
Employees
194
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$962.96K
Bought
$86.59K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $4.00 (+847.2%)

2 firms rating AKBA in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From AKBA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-8.71%
5 Days
-17.98%
1 Month
-31.43%
6 Months
-62.21%
1 Year
-75.75%

$AKBA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AKBA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AKBA's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AKBA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AKBA Revenue by Segment

$210.52MTotal
Beginning balance$77.09M36.62%
Ending balance$75.35M35.79%
Current provisions related to sales in current year$58.07M27.58%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AKBA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AKBA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AKBA

VTIVanguard Morningstar Total Stock Market ETF$4.41M
IWMiShares Russell 2000 ETF$2.89M
VXFVanguard Extended Market ETF$2.24M
VTWOVanguard Russell 2000 ETF$1.07M
IWOiShares Russell 2000 Growth ETF$944.25K
FESMFidelity Enhanced Small Cap ETF$879.34K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AKBA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
35

News check: Analyst downgrades and earnings miss outweigh patent grants and financing facility in driving bearish tone.

Recent Insider Activity

Buys
1
Sells
16
Buy Value
$86.59K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

QQQSInvesco NASDAQ Future Gen 200 ETF0.35%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.26%
SBIOALPS Medical Breakthroughs ETF0.09%
VHTVanguard Health Care ETF0.00%
FEACFidelity Covington Trust - Fidelity Enhanced U.S. All-Cap Equity ETF0.00%

Weight is the stock’s share of each fund’s holdings.